Financial Wire

Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat

-- Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported first-quarter results above market estimates.

The company now anticipates adjusted earnings of $5.38 to $5.58 per share for 2026, including a $0.20 dilution related to the Exact Sciences purchase. The company previously expected adjusted EPS to come in between $5.55 and $5.80 for the year, while the current consensus on FactSet is for $5.60.

Abbott acquired Exact Sciences in March.

"The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year," Abbott Chief Executive Robert Ford said in a statement.

Comparable sales, which includes the prior and current year sales of Exact Sciences, are pegged to grow by 6.5% to 7.5% for 2026, according to the company.

Abbott's shares fell 4.1% in Thursday trade, taking its year-to-date loss to 22%.

For the three-month period ended March, the firm's adjusted EPS rose to $1.15 from $1.09 the year before, surpassing the Street's view for $1.14. Sales improved 7.8% to $11.16 billion, topping the average analyst estimate of nearly $11 billion. Comparable sales were up 3.7%.

Diagnostics sales rose 6.1% year over year to $2.18 billion, while the nutrition segment dropped 6% to $2.02 billion amid lower sales volume and pricing actions in the previous quarter, according to the company. Revenue in the established pharmaceuticals division climbed 13% to $1.43 billion.

Sales in the global medical devices business jumped 13% to $5.54 billion, led by gains of 17% each in rhythm management and electrophysiology, Abbott said. Within the segment, the company recorded double-digit growth in heart failure and diabetes care.

For the second quarter, Abbott forecasts adjusted EPS of $1.25 to $1.31, while the Street is looking for $1.36.

Price: $97.09, Change: $-4.43, Percent Change: -4.36%

Related Articles

Research

Research Alert: CFRA Initiates Coverage On Shares Of Klarna Group Plc With A Hold Rating

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We initiate coverage on KLAR with a Hold rating and target of $16, 13.9x our 2028 EPS estimate, a discount to its historical trading average (38.7x) but more aligned with peers (13.6x). We project an LPS of $0.14 in 2026 and EPS of $0.68 in 2027 and $1.15 in 2028. While KLAR benefits from secular BNPL tailwinds and market-leading scale across 118M consumers and 966K merchants, near-term profitability remains pressured by Fair Financing's rapid expansion that front-loads provisions while deferring revenue recognition. The Klarna Card's explosive adoption and AI-led operational leverage provide compelling long-term upside, but execution risks cloud the outlook. Management has missed transaction margin dollar guidance despite beating revenue expectations, raising questions about its ability to forecast the P&L impact of its own strategic initiatives. A federal securities lawsuit alleging the IPO prospectus understated credit risk exposure adds near-term overhang as shares have fallen over 60% from the IPO price.

$KLAR
Asia

SUPCON's 2025 Profit Drops 60%, Revenue Slips 12%; Shares Down 5%

SUPCON Technology's (SHA:688777) net profit attributable to shareholders in 2025 dropped 60% to 441.5 million yuan from 1.12 billion yuan a year earlier, according to a Shanghai bourse filing on Tuesday.Earnings per share fell 61% year on year to 0.56 yuan from 1.42 yuan.Operating revenue slipped 12% to 8.07 billion yuan from 9.14 billion yuan in the previous year.The industrial automation control products manufacturer's shares fell 5% during the morning trade.

$SHA:688777
Asia

Aspial Lifestyle Prices SG$28 Million Worth of Bonds; Shares Up 7%

Aspial Lifestyle (SGX:5UF) priced SG$28 million worth of 5.10% bonds due 2029, under its SG$300 million multicurrency medium-term bond program, according to a Monday filing with the Singapore Exchange.Shares of the retail brand were up over 7% in Tuesday's late-morning trading.The bonds will be consolidated and form a single series with the existing SG$75 million 5.10% bonds due 2029.DBS Bank was appointed as the sole dealer for the bonds.Net proceeds raised from the issue of the bonds will be used for general corporate purposes.The bonds are expected to be listed on April 30, the filing added.

$SGX:5UF